Talazoparib loaded solid lipid nanoparticles: Preparation, characterization and evaluation of the therapeutic efficacy in vitro
dc.contributor.author | Eskiler, Gamze Güney | |
dc.contributor.author | Dikmen, Gökhan | |
dc.contributor.buuauthor | Çeçener, Gülşah | |
dc.contributor.buuauthor | Egeli, Ünal | |
dc.contributor.buuauthor | Tunca, Berrin | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı | tr_TR |
dc.contributor.orcid | 0000-0002-3820-424X | |
dc.contributor.orcid | 0000-0001-7904-883X | |
dc.contributor.orcid | 0000-0002-1619-6680 | |
dc.contributor.researcherid | AAP-9988-2020 | |
dc.contributor.researcherid | AAH-1420-2021 | |
dc.contributor.researcherid | ABI-6078-2020 | |
dc.contributor.scopusid | 6508156530 | |
dc.contributor.scopusid | 55665145000 | |
dc.contributor.scopusid | 6602965754 | |
dc.date.accessioned | 2024-05-15T11:37:15Z | |
dc.date.available | 2024-05-15T11:37:15Z | |
dc.date.issued | 2019 | |
dc.description.abstract | Objective: In the present work, we report for the first time the therapeutic potential of talazoparib (BMN 673)-SLNs for the treatment of BRCA1 deficient Triple Negative Breast Cancer (TNBC). BMN 673-SLNs were produced by hot-homogenization technique and then characterized. Methods: The cytotoxic and apoptotic effects of BMN 673-SLNs compared with BMN 673 were determined on HCC1937BRCA1-/-, HCC1937-R resistant TNBC and MCF-10A control cell lines. BMN 673- SLNs were found to have reduced particle size (219.5 ± 1.45 nm) and thus more stable (-28.4 ± 2.52 mV) than BMN 673 (1652 ± 2.46 nm and -18.6 ± 0.45 mV) at 4ºC. Results: In vitro cell line studies demonstrated that BMN 673-SLNs showed significant cytotoxic effects on HCC1937 (29.8%) and HCC1937-R cells (35.7%) at 10 nM for 12 days compared with BMN 673 (HCC1937 cells: 34.0% and HCC1937-R cells: 93.8% at 10 nM for 12 days) (p<0.05). Additionally, BMN 673-SLNs (40.1%) reduced the toxicity of BMN 673 (53.1%) on MCF-10A control cells thanks to unique physical properties. Conclusion: The apoptotic rates in the 10 nM BMN 673-SLNs treatment (88.78% and 85.56%) for 12 days were significantly higher than those in 10 nM BMN 673 (82.6% and 25.86%) for 12 days in HCC1937 and HCC1937-R cells, respectively (p<0.01). Furthermore, these effects were consistent with the findings of colony formation, wound healing and calcein accumulation analysis. In conclusion, the therapeutic potential of BMN 673-SLNs provides a promising chemotherapeutic strategy for the treatment of drugresistant TNBC. | en_US |
dc.identifier.citation | Eskiler, G. G. vd. (2019). " Talazoparib loaded solid lipid nanoparticles: Preparation, characterization and evaluation of the therapeutic efficacy in vitro", 16(6), 511-529. | en_US |
dc.identifier.doi | https://doi.org/10.2174/1567201816666190515105532 | |
dc.identifier.endpage | 529 | |
dc.identifier.issn | 1567-2018 | |
dc.identifier.issue | 6 | |
dc.identifier.pubmed | 31113350 | |
dc.identifier.scopus | 2-s2.0-85072849067 | |
dc.identifier.startpage | 511 | |
dc.identifier.uri | https://www.eurekaselect.com/article/98496 | |
dc.identifier.uri | https://hdl.handle.net/11452/41441 | |
dc.identifier.volume | 16 | |
dc.identifier.wos | 000483386900004 | |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Bentham Science Publisher | en_US |
dc.relation.bap | BUAP(T)-2015/1 | |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.journal | Current Drug Delivery | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Triple negative breast cancer (TNBC) | en_US |
dc.subject | PARP inhibitors | en_US |
dc.subject | Talazoparib (BMN 673) | en_US |
dc.subject | Solid lipid nanoparticles (SLNs) | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Cytotoxic effects | en_US |
dc.subject | Drug-delivery-systems | en_US |
dc.subject | Inhiıbitor Bmn 673 | en_US |
dc.subject | Parp Inhibitor | en_US |
dc.subject | DNA-repair | en_US |
dc.subject | Multidrug-resistance | en_US |
dc.subject | Synthetic lethality | en_US |
dc.subject | Highly potent | en_US |
dc.subject | Cancer | en_US |
dc.subject | Cytotoxicity | en_US |
dc.subject | Paclitaxel | en_US |
dc.subject.mesh | Antineoplastic agents | en_US |
dc.subject.mesh | Apoptosis | en_US |
dc.subject.mesh | BRCA1 protein | en_US |
dc.subject.mesh | Cell proliferation | en_US |
dc.subject.mesh | Dose-response relationship, drug | en_US |
dc.subject.mesh | Drug screening assays, antitumor | en_US |
dc.subject.mesh | Lipids | en_US |
dc.subject.mesh | Nanoparticles | en_US |
dc.subject.mesh | Phthalazines | en_US |
dc.subject.mesh | Structure-activity relationship | en_US |
dc.subject.mesh | Triple negative breast neoplasms | en_US |
dc.subject.mesh | Tumorcells | en_US |
dc.subject.mesh | Cultured | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.scopus | Olaparib; Ovarian Neoplasms; Homologous Recombination | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.title | Talazoparib loaded solid lipid nanoparticles: Preparation, characterization and evaluation of the therapeutic efficacy in vitro | en_US |
dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: